Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACHIEVE LIFE SCIENCES, INC.ACHV · Entity 5072 | Director | June 06, 2025 | June 10, 2025 |
| EyePoint, Inc.EYPT · Entity 5702 | Director | January 02, 2026 | January 06, 2026 |
| Foghorn Therapeutics Inc.FHTX · Entity 5820 | Director | June 24, 2026 | June 25, 2026 |
| Milestone Pharmaceuticals Inc.MIST · Entity 6561 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACHIEVE LIFE SCIENCES, INC.
Report date June 06, 2025 · Filed June 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.83 · Expires 2035-06-06 | Direct | 31,500 |
Reported balance
After 2025-06-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-06-06 · Grant · Acquired 31,500 · Balance 31,500 F1: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders.
EyePoint, Inc.
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.48 · Expires 2036-01-02 | Direct | 40,000 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 40,000 · Balance 40,000 |
Foghorn Therapeutics Inc.
Report date June 24, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.08 · Expires 2036-06-23 | Direct | 28,000 |
Reported balance
After 2026-06-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-24 · Grant · Acquired 28,000 · Balance 28,000 F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors.
Milestone Pharmaceuticals Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.22 · Expires 2036-06-10 | Direct | 77,000 |
Reported balance
After 2026-06-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-10 · Grant · Acquired 77,000 · Balance 77,000 F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 24, 2026 Filed Jun 25, 2026 20:06 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 28,000 | $4.08 Strike: $4.08 | $114,240.00 |
DisclosureSEC source: 0001970274-26-000007 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2036-06-23 F1 · derivative.exercise_date: The option vests in full on the first anniversary of the grant date, subject to the reporting person's continued service on the board of directors. Read SEC document |
| June 10, 2026 Filed Jun 12, 2026 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 77,000 | $0.00 Strike: $1.22 | $0.00 |
DisclosureSEC source: 0001970274-26-000004 · form4-06122026_040603.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,000 Underlying: Common Stock · 77,000 shares Expires 2036-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2026, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 6, 2026 21:06 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $17.48 | $0.00 |
DisclosureSEC source: 0001970274-26-000002 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-01-02 Read SEC document |
| June 10, 2025 Filed Jun 12, 2025 20:19 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.75 | $0.00 |
DisclosureSEC source: 0001415889-25-016929 · form4-06122025_040603.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-06-10 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on July 10, 2025, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| June 06, 2025 Filed Jun 10, 2025 20:45 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $3.83 | $0.00 |
DisclosureSEC source: 0000950170-25-084407 · ownership.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2035-06-06 F1 · derivative.exercise_date: The options vest 100% on the earlier of June 6, 2026 or the date immediately prior to the Issuer's 2026 annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:03 UTC | Foghorn Therapeutics Inc. FHTX · Entity 5820 | GrantStock Options (Right to buy) · Derivative | 50,000 | $4.16 Strike: $4.16 | $208,000.00 |
DisclosureSEC source: 0001562180-25-003474 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-04-30 F1 · derivative.exercise_date: The options will vest as to one-third of the underlying shares of common stock on each of the first three anniversaries of the date of grant, subject to the recipient's continuing service on the board of directors. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 21:04 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $8.26 | $0.00 |
DisclosureSEC source: 0001562180-25-000232 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2035-01-03 Read SEC document |
| August 28, 2024 Filed Aug 29, 2024 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001415889-24-022536 · form4-08292024_040810.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-08-28 F1 · derivative.exercise_date: This option will vest in twelve (12) equal monthly installments, beginning on September 28, 2024, provided that the option will in any case be fully vested on the date of next annual meeting of the stockholders of the Issuer, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 20:15 UTC | Milestone Pharmaceuticals Inc. MIST · Entity 6561 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.59 | $0.00 |
DisclosureSEC source: 0001415889-24-019664 · form4-07172024_080751.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Shares · 80,000 shares Expires 2034-07-15 F1 · derivative.exercise_date: This option will vest in equal monthly installments, beginning on August 15, 2024, over a period of three years, subject to the Reporting Person continuing to provide service through each such vesting date. Read SEC document |
| January 22, 2024 Filed Jan 25, 2024 00:20 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 31,500 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001209191-24-002205 · doc4.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,500 Underlying: Common Stock · 31,500 shares Expires 2034-01-22 F1 · derivative.exercise_date: The options vest 100% on the earlier of 18 months from the grant date or the date immediately prior to the Issuer's 2025 annual meeting of stockholders. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:54 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 25,014 | $0.00 Strike: $20.40 | $0.00 |
DisclosureSEC source: 0001562180-24-000394 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,014 Underlying: Common Stock · 25,014 shares Expires 2034-01-04 Read SEC document |
| October 16, 2023 Filed Oct 17, 2023 20:49 UTC | EyePoint, Inc. EYPT · Entity 5702 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $8.23 | $0.00 |
DisclosureSEC source: 0001562180-23-007327 · primarydocument.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2033-10-15 F1 · derivative.exercise_date: The option becomes exercisable in three ratable annual installments beginning on October 16, 2024. Read SEC document |
| March 29, 2023 Filed Mar 30, 2023 15:25 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001209191-23-021584 · doc4.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-03-29 F1 · derivative.exercise_date: The options vest on the one month anniversary of March 29, 2023 and thereafter in monthly installments over 36 months. Read SEC document |
| March 29, 2023 Filed Jun 9, 2023 20:15 UTC | ACHIEVE LIFE SCIENCES, INC. ACHV · Entity 5072 | GrantStock Option (right to buy) · Derivative | 23,250 | $0.00 Strike: $5.97 | $0.00 |
DisclosureSEC source: 0001209191-23-035785 · doc4.xml · derivative · entry 1 Duty Stuart · CIK 0001970274 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,250 Underlying: Common Stock · 23,250 shares Expires 2033-03-29 F1 · derivative.exercise_date: These options were granted on March 29, 2023 (the "Grant Date") pursuant to the 2023 Non-Employee Director Equity Incentive Plan (the "Plan"), subject to the Plans approval by the Issuers stockholders. The Plan was approved by the Issuers stockholders at the Issuers 2023 Annual Meeting of Stockholders on June 7, 2023. These options will vest on the one month anniversary of the Grant Date and thereafter in monthly installments over 36 months. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.